Literature DB >> 15201984

A short region of the promoter of the breast cancer associated PLU-1 gene can regulate transcription in vitro and in vivo.

Aurélie Catteau1, Ian Rosewell, Ellen Solomon, Joyce Taylor-Papadimitriou.   

Abstract

The recently cloned gene PLU-1 shows restricted expression in adult tissues, with high expression being found in testis, and transiently in the pregnant mammary gland. However, both the gene and the protein product are specifically up-regulated in breast cancer. To investigate the control of expression of the PLU-1 gene, we have cloned and functionally characterised the 5' flanking region of the gene, which was found to contain another putative gene. Two transcription start sites of the PLU-1 gene were mapped by 5' RACE. A short proximal 249 bp region was defined using reporter gene assays, which encompasses the major transcription start site and exhibits a strong constitutive promoter activity in all cell lines tested. However, regions upstream of this sequence repress transcription more effectively in a non-malignant breast cell line as compared to breast cancer cell lines. The 249 bp region is GC-rich and includes consensus Sp1 sites, GC boxes, cAMP-responsive element (CRE) and other putative cis-elements. Mutational analysis showed that two intact conserved Sp1 binding sites (shown here to bind Sp1 and/or Sp3) are critical for constitutive promoter activity, while a negative role for a neighbouring GC box is indicated. The sequence of the core promoter is highly conserved in the mouse and Plu-1 expression in the mouse embryo has been documented. Using transgenesis, we therefore examined the ability of the 249 bp fragment to control expression of a reporter gene during embryogenesis. We found that not only is the core promoter sufficient to activate transcription in vivo, but that the expression of the reporter gene coincides both temporally and spatially with regions where endogenous Plu-1 is highly expressed. This suggests that tissue specific controlling elements are found within the short fragment and are functional in the embryonic environment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15201984

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  5 in total

1.  Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression.

Authors:  Chun-Han Chen; Po-Hsien Huang; Po-Chen Chu; Mei-Chuan Chen; Chih-Chien Chou; Dasheng Wang; Samuel K Kulp; Che-Ming Teng; Qianben Wang; Ching-Shih Chen
Journal:  J Biol Chem       Date:  2011-01-31       Impact factor: 5.157

2.  Effects of Histone Deacetylase Inhibitors on Modulating H3K4 Methylation Marks - A Novel Cross-Talk Mechanism between Histone-Modifying Enzymes.

Authors:  Po-Hsien Huang; Christoph Plass; Ching-Shih Chen
Journal:  Mol Cell Pharmacol       Date:  2011

3.  Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases.

Authors:  Po-Hsien Huang; Chun-Han Chen; Chih-Chien Chou; Aaron M Sargeant; Samuel K Kulp; Che-Ming Teng; John C Byrd; Ching-Shih Chen
Journal:  Mol Pharmacol       Date:  2010-10-19       Impact factor: 4.436

4.  Msc1 acts through histone H2A.Z to promote chromosome stability in Schizosaccharomyces pombe.

Authors:  Shakil Ahmed; Barbara Dul; Xinxing Qiu; Nancy C Walworth
Journal:  Genetics       Date:  2007-10-18       Impact factor: 4.562

5.  RSV-Induced H3K4 Demethylase KDM5B Leads to Regulation of Dendritic Cell-Derived Innate Cytokines and Exacerbates Pathogenesis In Vivo.

Authors:  Catherine Ptaschinski; Sumanta Mukherjee; Martin L Moore; Mareike Albert; Kristian Helin; Steven L Kunkel; Nicholas W Lukacs
Journal:  PLoS Pathog       Date:  2015-06-17       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.